Common adverse effects reported with belimumab include nausea, diarrhea, fever, as well as hypersensitivity and infusion-site reactions (severe in 0.9% of patients). It is suggested that patients be treated with an [[antihistamine]] prior to a belimumab infusion.<ref name="EMA">[[European Medicines Agency]]: [http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002015/WC500110150.pdf Benlysta Summary of Product Characteristics]</ref>

 


 
A greater number of serious infections and deaths were reported in patients treated with belimumab than in those treated with [[placebo]]. Infections are due to the immunosuppressant properties of the drug.<ref>{{cite web|url=http://www.gsk.com/media/pressreleases/2011/2011_us_pressrelease_10017.htm |title=GlaxoSmithKline and Human Genome Sciences announce FDA approval of Benlysta (belimumab) for the treatment of systemic lupus erythematosus |accessdate=11 March 2011 |date=9 March 2011 |publisher=GlaxoSmithKline |deadurl=yes |archiveurl=https://web.archive.org/web/20110317151651/http://www.gsk.com/media/pressreleases/2011/2011_us_pressrelease_10017.htm |archivedate=March 17, 2011 }}</ref>

 

